Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca to present new cardiovascular data on Farxiga in type-2 diabetes at ACC 2019

First sub-analyses from Phase III DECLARE-TIMI 58 trial selected for
late-breaking clinical trial and oral presentations

Data evaluating the cardiovascular (CV) effects of Farxiga
(dapagliflozin), including hospitalisation for heart failure (hHF) in
adults with type-2 diabetes (T2D) have been selected for
late-breaking clinical trial and oral presentations at the American
College of Cardiology's (ACC) 68th Annual Scientific Session on 16-18
March. The data are the first sub-analyses from the Phase III
DECLARE-TIMI 58 trial for Farxiga.

AstraZeneca will also present the latest results from the Brilinta
(ticagrelor) Phase III TREAT trial in patients with the most
dangerous form of heart attack, ST-segment elevation myocardial
infarction (STEMI), and a new heart failure analysis from CVD-REAL,
the first large real-world evidence study of its kind evaluating the
risk of all-cause death and hHF in patients with T2D receiving
treatment with a SGLT2 inhibitor (SGLT2i), including Farxiga.

Joris Silon, Senior Vice President, Cardiovascular, Renal and
Metabolism, BioPharmaceuticals, said: "AstraZeneca is committed to
addressing some of the most pressing health problems faced by
patients with cardiovascular and metabolic diseases, by identifying
and mitigating specific risks. This is particularly important in
reducing the prevalence and burden of heart failure. This disease
affects nearly 64 million people globally, and is an early and
frequent complication in patients with type-2 diabetes."

AstraZeneca will present 21 abstracts at ACC 2019. Highlights include
(all times are Central):

Farxiga Phase III DECLARE-TIMI 58

· Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2
Diabetes and Prior Myocardial Infarction: A Sub-Analysis From DECLARE
TIMI-58 Trial (Oral Presentation: #906-04. Monday 18 March, 8:12-
8:22 AM, Room 211).

· Effect of Dapagliflozin on Heart Failure and Mortality in Type 2
Diabetes Mellitus Based on Ejection Fraction (Late-Breaking Clinical
Trial Presentation: #409-14. Monday 18 March, 8:45-8:55 AM, Main
Tent, Great Hall).

Brilinta Phase III TREAT

TREAT was designed to evaluate the safety and efficacy of Brilinta
compared with clopidogrel in patients who were diagnosed with STEMI
treated with pharmacological thrombolysis.

· Efficacy of Ticagrelor vs Clopidogrel After Fibrinolytic Therapy
in Patients With ST-Elevation Myocardial Infarction (Late-Breaking
Clinical Trial Presentation: #410-12. Monday 18 March, 11:15-11:25
AM, Main Tent, Great Hall).

Real-world evidence

New data on the increased and persistent risk of recurrent CV events
in patients with CV disease and additional risk factors, and outcomes
of patients with T2D with reduced or preserved ejection fraction.

· Novel Approach to Quantifying Risk of Major Cardiovascular Events
in Patients 1-3 Years Post-Myocardial Infarction: Insights From the
Global Prospective TIGRIS Registry (Poster Presentation: #1131-407.
Saturday 16 March, 10:00-10:45 AM, Poster Hall, Hall F).

· Use of Evidence-Based Preventive Medical Therapies 1-3 Years
Post-Myocardial Infarction in the Prospective Global TIGRIS Registry
(Poster Presentation: #1231-391. Sunday 17 March, 9:45-10:30 PM,
Poster Hall, Hall F).

· US Burden of Illness in a Commercially-Insured Population and
Assessment of The High risk and unmEt Need in patients with CAD and
type 2 diabetes (ATHENA): US Burden of Illness in the Diabetes
Collaborative Registry (Poster Presentation: #1129-361 and #1129-362.
Saturday 16 March, 10:00-10:45 PM, Poster Hall, Hall F).

· Initiation of Sodium Glucose Cotransporter-2 Inhibitors Versus
Other Glucose Lowering Drugs and Risk of Hospitalization For Heart
Failure and Death in Patients With Type 2 Diabetes With Reduced and
Preserved Left Ventricular Ejection Fraction (Moderated Poster
Presentation: #1024-07. Sunday 17 March, 10:15-10:25 AM, Poster Hall,
Hall F).

For a complete list of AstraZeneca data presentations at ACC 2019,
please access the ACC website here



About AstraZeneca in Cardiovascular, Renal & Metabolism (CVRM)

Cardiovascular, renal and metabolic diseases together form one of
AstraZeneca's main therapy areas and a key growth driver for the
Company. By following the science to understand more clearly the
underlying links between the heart, kidney and pancreas, AstraZeneca
is investing in a portfolio of medicines to protect organs and
improve outcomes by slowing disease progression, reducing risks and
tackling co-morbidities. Our ambition is to modify or halt the
natural course of CVRM diseases and potentially regenerate organs and
restore function, by continuing to deliver transformative science
that improves treatment practices and cardiovascular health for
millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal & Metabolism
and Respiratory. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide. For
more information, please visit and follow us on
Twitter @AstraZeneca.

Media Relations
Gonzalo Viña UK/Global +44 203 749 5916
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Jennifer Hursit UK/Global +44 203 749 5762
Christina Sweden +46 8 552 53 106
Michele US +1 302 885 2677

Thomas Kudsk +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer BioPharma - Cardiovascular; Metabolism +44 203 749 5711
Nick Stone BioPharma - Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Retail Investors; Corporate Access +44 203 749 5824
US toll-free +1 866 381 72 77


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.